Learning from a clinical cohort for HCV vaccine development
- PMID: 30992137
- PMCID: PMC7613475
- DOI: 10.1016/j.jhep.2019.03.030
Learning from a clinical cohort for HCV vaccine development
Keywords: Antibody; B-cell response; Hepatitis C virus; Neutralization.
Conflict of interest statement
Comment on
-
Cross-genotype AR3-specific neutralizing antibodies confer long-term protection in injecting drug users after HCV clearance.J Hepatol. 2019 Jul;71(1):14-24. doi: 10.1016/j.jhep.2019.02.013. Epub 2019 Feb 21. J Hepatol. 2019. PMID: 30797052
References
-
- Baumert TF, Fauvelle C, Chen DY, Lauer GM. A prophylactic hepatitis C virus vaccine: a distant peak still worth climbing. J Hepatol. 2014;61:S34–44. - PubMed
-
- Gerlach JT, Diepolder HM, Jung MC, Gruener NH, Schraut WW, Zachoval R, et al. Recurrence of hepatitis C virus after loss of virus-specific CD4(+) T-cell response in acute hepatitis C. Gastroenterology. 1999;117:933–941. - PubMed
Publication types
MeSH terms
Substances
Grants and funding
LinkOut - more resources
Full Text Sources
Medical